Novavax Secures Global Approvals for Updated XFG COVID-19 Vaccine

The Gaithersburg-based company continues to lean on its licensing strategy, outsourcing commercial infrastructure to established pharmaceutical giants. Sanofi, which manages the majority of global markets for the vaccine, is scaling up distribution in the U.S. and launching in Canada and Germany. Meanwhile, Takeda remains a dominant force in Japan, where Nuvaxovid secured its position as the second-most utilized COVID-19 vaccine during the previous season.

Novavax CEO John C. Jacobs highlighted the model as a core driver of value, noting that the company can generate revenue without the burden of maintaining its own commercial sales force. Beyond the business structure, the company is pointing to data from Sanofi’s Phase 4 COMPARE study to differentiate its product. The study suggests a favorable tolerability profile for the protein-based, non-mRNA vaccine compared to next-generation alternatives, a factor Novavax hopes will influence patient and provider preference as public health concerns persist for high-risk populations.